Clinical Trial Update: A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA) [Phase 3]

View source ↗

Summary

Phase 3 trial investigating baricitinib (LY3009104) in children aged 1 year to under 18 with systemic juvenile idiopathic arthritis; status is active but not re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Juvenile Idiopathic Arthritis

Drugs mentioned

• Baricitinib (baricitinib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Systemic Juvenile Idiopathic Arthritis | Phase 3 | Status: ACTIVE_NOT_RECRUITING